We're Keeping An Eye On Solasia Pharma K.K's (TSE:4597) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?
So, the natural question for Solasia Pharma K.K (TSE:4597) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.
How Long Is Solasia Pharma K.K's Cash Runway?
A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Solasia Pharma K.K last reported its March 2026 balance sheet in May 2026, it had zero debt and cash worth JP¥1.6b. In the last year, its cash burn was JP¥1.1b. That means it had a cash runway of around 17 months as of March 2026. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. The image below shows how its cash balance has been changing over the last few years.
Check out our latest analysis for Solasia Pharma K.K
How Well Is Solasia Pharma K.K Growing?
Solasia Pharma K.K boosted investment sharply in the last year, with cash burn ramping by 70%. On the bright side, at least operating revenue was up 24% over the same period, giving some cause for hope. In light of the data above, we're fairly sanguine about the business growth trajectory. Of course, we've only taken a quick look at the stock's growth metrics, here. You can take a look at how Solasia Pharma K.K has developed its business over time by checking this visualization of its revenue and earnings history.
How Easily Can Solasia Pharma K.K Raise Cash?
Solasia Pharma K.K seems to be in a fairly good position, in terms of cash burn, but we still think it's worthwhile considering how easily it could raise more money if it wanted to. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.
Solasia Pharma K.K has a market capitalisation of JP¥8.5b and burnt through JP¥1.1b last year, which is 13% of the company's market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.
So, Should We Worry About Solasia Pharma K.K's Cash Burn?
On this analysis of Solasia Pharma K.K's cash burn, we think its revenue growth was reassuring, while its increasing cash burn has us a bit worried. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. An in-depth examination of risks revealed 4 warning signs for Solasia Pharma K.K that readers should think about before committing capital to this stock.
Of course Solasia Pharma K.K may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.